Interatrial septal device therapy in  HFpEF

Interatrial septal device therapy in HFpEF Effective therapeutic modalities for heart failure with preserved ejection fraction (HFpEF) are lesser than those available for heart failure with reduced ejection fraction (HFrEF). All the same, prevalence, morbidity and mortality for HFpEF are not lower than that of HFrEF. Ongoing search for therapeutic options has led to the development of interatrial septal devices to decompress the left atrium, which are still in investigational phase [1]. A unidirectional left-to-right interatrial shunting device was initially tested in patients with HFrEF as a safety and proof-of-principle cohort study. The device could be successfully implanted in all the 10 patients enrolled with no device or procedure related adverse events. Transesophageal echocardiography at one month showed patent shunts with no thrombosis or migration. NYHA functional class improved in all but one. No patient was admitted to hospital for worsening of heart failure. One patient died at 2 months with incessant ventricular tachycardia and heart failure [2]. REDUCE LAP-HF was a multicentre, open-label, single-arm, phase 1 trial of another type of interatrial septal device for HFpEF. Twenty-one centres across two continents participated in the trial. Successful device placement could be achieved in 64 of the 68 patients enrolled. No patient had a peri-procedural or major adverse cardiac or cerebrovascular event or need for cardiac surgical intervention for device related co...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: General Cardiology Source Type: blogs